drugset / Trial / NCT04944966

Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria

NCT04944966

RandomizedParallel-groupOpen-labelTreatment

Summary

Antimalarial Herbal medicine known as Maytenus senegalensis will be evaluated for its safety, tolerability and efficacy among Tanzanian male adults aged 18 to 45 years. The first primary objective is to assess the safety and tolerability of malaria herbal remedy of Maytenus senegalensis among healthy male adults aged 18 to 45 years in Tanzania. And the second objective is to evaluate the safety, tolerability as well as efficacy of malaria herbal remedy Maytenus senegalensis (MALHERBAL) for the treatment of Tanzanian adults aged 18 to 45 years with uncomplicated malaria compared to Artemether-lumefantrine.

Timeline

Start
2021-06-02
Primary completion
2022-09-25
Completion
2022-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Artemether-lumefantrine Unknown 400 mg Oral
Subject Artemether-lumefantrine Unknown 600 mg Oral
Subject Artemether-lumefantrine Unknown 800 mg Oral

Indications